Skip to main navigation Skip to search Skip to main content

The role of surgery in the treatment of recurrent gastric cancer

  • The Catholic University of Korea

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

Background: The purpose of the current study was to determine the role of surgery in the treatment of recurrent gastric cancer. Methods: Of the 347 patients with recurrent gastric cancer, 61 patients (17.8%) who underwent surgery were evaluated retrospectively. The underlying causes and types of surgery, survival, and postoperative quality of life were analyzed. Results: The most common cause of surgery was intestinal obstruction due to carcinomatosis. Complete resection was possible in 15 patients (24.6 %), including 10 gastric remnant recurrences, and 2 hepatic and 3 ovarian metastases. The survival of patients who had complete resection was significantly longer than the other groups (52.2 months for complete resections, 13.1 months for palliative procedures, and 8.7 months for laparotomy alone, respectively) (P < .05). The median hospital-free survival (HFS) durations were 9.4, 2.9, and 2.2 months for incomplete resection, bypass/enterostomy, and laparotomy only, respectively (P < .05). Conclusion: Surgical treatment in recurrent gastric cancer is rarely indicated; however, if complete resection could be accomplished, long-term survival can be expected. Bypass surgery for symptom palliation did not increase the HFS.

Original languageEnglish
Pages (from-to)19-22
Number of pages4
JournalAmerican Journal of Surgery
Volume196
Issue number1
DOIs
StatePublished - Jul 2008

Bibliographical note

Funding Information:
Supported in part by the Catholic Cancer Center.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Gastric cancer
  • Recurrence
  • Role
  • Surgery

Fingerprint

Dive into the research topics of 'The role of surgery in the treatment of recurrent gastric cancer'. Together they form a unique fingerprint.

Cite this